期刊文献+

利福平微球-原位凝胶复合给药系统的研究 被引量:6

Study on Rifampicin Microspheres-In Situ Gel Complex Drug Delivery System
原文传递
导出
摘要 目的制备利福平聚乳酸-羟基乙酸共聚物(PLGA)微球-原位凝胶复合给药系统用于结核病局部给药,以达到局部滞留、缓慢释放的作用。方法采用液中干燥法制备微球,用海藻酸钠制成离子敏感型原位凝胶,考察微球以及复合给药系统的体外药物释放情况,初步考察复合给药系统在大鼠肺部的胶凝时间。结果微球平均粒径为149.569μm,包封率(n=3)为(69.43±3.53)%,载药量(n=3)为(26.43±3.10)%,体外释放实验表明,微球-原位凝胶复合给药系统有抑制药物突释的作用,且药物在30 d内释放25%,大鼠肺部胶凝实验表明,离子敏感型原位凝胶在大鼠肺部可滞留6 h。结论利福平PLGA微球-原位凝胶复合给药系统达到了局部滞留、缓慢释放药物的目的。 OBJECTIVE To prepare RFP-microspheres-in situ gel complex drug delivery system(CDDS) for topical administration, achieve the local retention and sustained release function. METHODS The RFP-loaded microspheres were fabricated by a modified emulsification/solvent diffusion method, sodium alginate for in situ gel. The drug release from microspheres and CDDS were investigated. Gelatinization time of CDDS were studied preliminarily in lung of SD rats. RESULTS Average particle size of MS was 149. 569 μm, entrapment rate and drug-loading rate ( n = 3 ) were ( 69. 43 ± 3.53 ) % and ( 26.43 ± 3. 10 ) %. The study shows that CDDS may reduce dumping in vitro and drug release 25% for 30 d. CONCLUSION RFP microspheres-in situ gel complex drug delivery system can local retention and sustained release.
出处 《中国药学杂志》 CAS CSCD 北大核心 2011年第4期283-286,共4页 Chinese Pharmaceutical Journal
基金 "十一五"科技重大专项(2008ZX10003-016)
关键词 利福平 聚乳酸羟基乙酸共聚物 微球 离子敏感型原位凝胶 体外释放 rifampicin PLGA microspheres ion-activated in situ gel release in vitro
  • 相关文献

参考文献4

二级参考文献19

  • 1王安生,王巍,林明贵,陈红兵,李素梅.含药凝胶介入治疗耐多药空洞肺结核的初步临床研究[J].中国防痨杂志,2005,27(1):26-28. 被引量:22
  • 2陈新谦,新编药物学(第13版),1992年
  • 3高宏科,中国医院药学杂志,1988年,8卷,12期,564页
  • 4张梅,中国医院药学杂志,1985年,5卷,1期,28页
  • 5袁锁中,药学通报,1982年,17卷,7期,16页
  • 6王明远,药学通报,1980年,15卷,3期,6页
  • 7张万国,第二军医大学学报,1996年,17卷,395页
  • 8张万国,中国抗生素杂志,1996年,21卷,273页
  • 9王剑红,药学学报,1995年,30卷,549页
  • 10徐叔云,临床用药指南,1987年,163页

共引文献44

同被引文献50

  • 1张南生,陈瑞杰,张秀华.利福平不良反应的文献分析[J].中国临床药学杂志,2005,14(5):312-315. 被引量:31
  • 2束家有,全向阳,束怡,广一平,刘有成.月桂酸二乙醇酰胺修饰利福喷丁脂质体的制备、性质及肺部给药[J].药学学报,2006,41(8):761-764. 被引量:7
  • 3但敏,李斌,陈枫,郭爱波,刘玉萍,刘明海,胡希伟.羟基磷灰石(HA)的制备方法及其研究进展[J].现代生物医学进展,2006,6(11):125-127. 被引量:8
  • 4Agrawal YK,Bhatth HG, Raval HG,et al.Emerging trends in tuberculo- sis therapy[J] .J Sci lnd Res,2007,66(3):191.
  • 5Manca ML, Momtas S, Dracopoulos V, et al. PLGA, chitosan or chitosm- coated PLGA mieropartides for alveolar delivery? A comparative study of partide stability during nebulization [ J]. Colloids Surf B Biointeffaces, 2008,62(2):220.
  • 6Liu MX, Dong J, YANG YJ,et al. Characterization and release of trip- tolide-loaded poly( D, L-lactic acid ) nanoparticles[ J]. Eur Pol J,2005, 41 (2) : 375.
  • 7Kwon BJ,Kim J,Kim YH,et al.Biological advantages of poroushydroxyapatite scaffold made by solid freeform fabrication for bonetissue regeneration[J].Artif Organs,2013,37(7):663-670.
  • 8Zhuang Z,Fujimi TJ,Nakamura M,et al.Development of a,b-plane-oriented hydroxyapatite ceramics as models for living bonesand their cell adhesion behavior[J].Acta Biomater,2013,9(5):6732-6740.
  • 9Zhou H,Zhang Y,Biggs DL,et al.Microparticle-based lung de-livery of INH decreases INH metabolism and targets alveolar mac-rophages [J].J Control Release,2005,107(2):288-299.
  • 10Dutt M,KhulIer GK.Chemotherapy of Mycobacterium tuberculo-sis infections in mice with a combination of isoniazid and rifampi-cin entrapped in Poly(DL-lactide-co-glycolide)microparticles[J].J Antimicrob Chemother,2001,47(6):829-835.

引证文献6

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部